Balamapimod

CAS No. 863029-99-6

Balamapimod( MKI-833 | MKI833 )

Catalog No. M16245 CAS No. 863029-99-6

Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Balamapimod
  • Note
    Research use only, not for human use.
  • Brief Description
    Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential.
  • Description
    Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    MKI-833 | MKI833
  • Pathway
    MAPK/ERK Signaling
  • Target
    Raf
  • Recptor
    Raf
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    863029-99-6
  • Formula Weight
    574.144
  • Molecular Formula
    C30H32ClN7OS
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N#CC1=C(NC2=CC=C(SC3=NC=CN3C)C(Cl)=C2)C4=CC(OC)=C(N5CCC(N6CCCC6)CC5)C=C4N=C1
  • Chemical Name
    4-[[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]amino]-6-methoxy-7-[4-(1-pyrrolidinyl)-1-piperidinyl]-3-quinolinecarbonitrile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • RMC-0331

    RMC-0331 (RM-023) is an orally available and potent SOS1 inhibitor with potential anticancer activity, blocking RAS activation by disrupting RAS-SOS1 interactions.

  • GDC-0879

    A potent and selective B-Raf kinase inhibitor with IC50 of 0.13 nM against purified B-Raf V600E and a cellular pERK IC50 of 63 nM in the MALME-3M cell line.

  • LXH254

    LXH254 (LXH-254, LXH 254) is a novel potent, ATP-competitive pan-RAF inhibitor, binds to Raf proteins and inhibits Raf-mediated signal transduction pathways.